Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Expenses (2021 - 2025)

ARS Pharmaceuticals' Operating Expenses history spans 5 years, with the latest figure at $69.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 76.6% year-over-year to $69.6 million; the TTM value through Dec 2025 reached $263.7 million, up 185.94%, while the annual FY2025 figure was $263.7 million, 185.94% up from the prior year.
  • Operating Expenses for Q4 2025 was $69.6 million at ARS Pharmaceuticals, down from $85.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $85.7 million in Q3 2025 and bottomed at -$41.1 million in Q4 2021.
  • The 5-year median for Operating Expenses is $19.3 million (2021), against an average of $24.3 million.
  • The largest annual shift saw Operating Expenses tumbled 69.94% in 2022 before it surged 316.88% in 2023.
  • A 5-year view of Operating Expenses shows it stood at -$41.1 million in 2021, then skyrocketed by 105.97% to $2.5 million in 2022, then soared by 316.88% to $10.2 million in 2023, then soared by 285.14% to $39.4 million in 2024, then surged by 76.6% to $69.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Operating Expenses are $69.6 million (Q4 2025), $85.7 million (Q3 2025), and $63.3 million (Q2 2025).